PCSK9 inhibition with orally administered NNC0385-0434 in hypercholesterolaemia: a randomised, double-blind, placebo-controlled and active-controlled phase 2 trial
This story is reported by The Lancet. Read what other outlets are saying below, then open the original report for full details.